Valerian extract characterized by high valerenic acid and low acetoxy valerenic acid contents demonstrates anxiolytic activity

Phytomedicine

Volumn 19, Issue 13, 2012, Pages 1216-1222

  Felgentreff, F ^a   Becker, A ^a   Meier, B ^b   Brattstrom A ^c  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b ZURICH UNIVERSITY OF APPLIED SCIENCES   (Switzerland)

^c NONE   (Germany)

Author keywords

Anxiety; Body core temperature; Elevated plus maze; Tail suspension test; Valerenic acid; Valerian extract

Indexed keywords

ACETOXY VALERENIC ACID; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; DIAZEPAM; IMIPRAMINE; UNCLASSIFIED DRUG; VALERENIC ACID; VALERIAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORE TEMPERATURE; DRUG EFFICACY; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY;

VALERIANA;

EID: 84866734716     PISSN: 09447113     EISSN: 1618095X     Source Type: Journal    
DOI: 10.1016/j.phymed.2012.08.003     Document Type: Article

References (30)

1. J.R. Atack The benzodiazepine binding site of GABAA receptors as a target for the development of novel anxiolytics Expert Opinion on Investigational Drugs 14 2005 601 618 (Pubitemid 40790282)
2. J.R. Atack GABAA receptor subtype-selective modulators. I. α2/α3 - selective agonist as non-sedating anxiolytics Current Topics Medicinal Chemistry 11 2011 1176 1202
3. N.A. Ator, J.R. Atack, R.J. Hargreaves, D. Burns, and G.R. Dawson Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at α1 and α2/3 subtypes Journal of Pharmacology and Experimental Therapeutics 332 2010 4 16
4. D. Benke, A. Barberis, S. Kopp, K.H. Altmann, M. Schubiger, K.E. Vogt, U. Rudolph, and H. Möhler GABAA receptors as in vivo substrate fort he anxiolytic action of valerenic acid, a major constituent of valerian root extracts Neuropharmacology 56 1 2009 174 181
5. S. Bent, A. Padula, D. Moore, M. Patterson, and W. Mehling Valerian for sleep: a systematic review and meta-analysis American Journal of Medicine 119 2006 1005 1012 (Pubitemid 44826933)
6. A. Brattström Scientific evidence for a fixed extract combination (Ze 91019) from valerian and hops traditionally used as a sleep-inducing aid Wiener Medizinische Wochenschrift 157 2007 367 370 (Pubitemid 47356266)
7. A. Buhr, M.T. Bianchi, R. Baur, P. Courtet, V. Pignay, J.P. Boulenger, S. Gallati, D.J. Hinkle, R.L. Macdonald, and E. Sigel Functional characterization of the new human GABA(A) receptor mutation bet3 (R192H) Human Genetics 111 2002 154 160 (Pubitemid 36075033)
8. J.F. Cryan, C. Mombereau, and A. Vassout The tail suspension test as a model for assessing antidepressant activity: a review of pharmacological and genetic studies in mice Neuroscience and Biobehavioral Reviews 29 2005 571 625 (Pubitemid 40755457)
9. F. Da Settino, S. Taliani, M.L. Trincavelli, M. Montali, and C. Martini GABAA/Bz receptor subtypes as target for selective drugs Current Medicinal Chemistry 14 2007 2680 2701
10. M. Ernst, S. Bruckner, S. Boresch, and W. Sieghart The comparative models of GABAA receptor extracellular and transmembrane domains: important insights in pharmacology and function Molecular Pharmacology 68 2005 1291 1300 (Pubitemid 41539985)
11. F. Haffner Die pharmakologische Wertbestimmung des Baldrians Munchener Medizinische Wochenschrift 7 1929 271 272
12. M. Hattesohl, B. Feistel, H. Sievers, R. Lehnfeld, M. Hegger, and H. Winterhoff Extracts of Valeriana officinalis L. s.I. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties Phytomedicine 15 2008 2 15 (Pubitemid 50021760)
13. G.A.R. Johnston GABAA receptor channel pharmacology Current Pharmaceutical Design 11 2005 1867 1885
14. S. Khom, I. Baburin, E. Timin, A. Hohaus, G. Trauner, B. Kopp, and S. Hering Valerenic acid potentiates and inhibits GABAA receptors: molecular mechanism and subunit specificity Neuropharmacology 53 1 2007 178 187 (Pubitemid 47125958)
15. S. Khom, B. Strommeier, J. Ramharter, T. Schwarz, C. Shwarzer, T. Erker, G.F. Ecker, J. Mulzer, and S. Hering Valerenic acid derivatives as novel subunit-selective ligands - in vitro and in vivo characterization British Journal of Pharmacology 161 1 2010 65 78
16. H.J. Kim, I. Baburin, S. Khom, S. Hering, and M. Hamburger HPLC-based activity profiling approach for the discovery of GABAA receptor ligands using an automated two electrode voltage clamp assay on Xenopus oocytes Planta Medica 74 2008 521 526 (Pubitemid 351655969)
17. A.D. Laposky, G.E. Homanics, A. Basile, and W.B. Mendelson Deletion of the GABA(A) receptor beta 3 subunit eliminates the hypnotic actions of oleamide in mice Neuroreport 12 2001 4143 4147 (Pubitemid 33152468)
18. H. Möhler GABA(A) receptor diversity and pharmacology Cell and Tissue Research 326 2006 505 516
19. K. Murphy, Z.J. Kubin, J.N. Shepherd, and R.H. Ettinger Valeriana officinalis root extracts have potent anxiolytic effects in laboratory rats Phytomedicine 17 2010 674 678
20. A. Navarrete, B. Avula, and Y.W. Choi Chemical fingerprinting of valerian species: simultaneous determination of valerenic acids, flavonoids, and phenylpropanoids using liquid chromatography with ultraviolet detection Journal of AOAC International 89 2006 8 18
21. R.W. Olsen, and W. Sieghart Internationale Union of Pharmacology. LXX. Subtypes of γ-aminobutyric acid A receptors: classification on the basis of subunit composition, pharmacology, and function. Update Pharmacological Review 60 3 2008 242 260
22. J. Ramerstorfer, R. Furtmüller, I. Sarto-Jackson, Z. Varagic, and W. Siehart The GABAA receptor α + β-interface: a novel target for subtype selective drugs Journal of Neuroscience 31 2011 870 877
23. R.J. Rodgers Animal models of anxiety: where next? Behavioural Pharmacology 8 1997 477 496 (Pubitemid 27504695)
24. R. Rupprecht, D. Eser, P. Zwanzger, and H.J. Möller GABAA receptors as targets for novel anxiolytic drugs The World Journal of Biological Psychiatry 7 2006 231 237 (Pubitemid 44650532)
25. K. Sichardt, Z. Vissiennon, U. Koetter, A. Brattström, and K. Nieber Modulation of postsynaptic potentials in rat cortical neurons by valerian extracts macerated with different alcohols: involvement of adenosines A1- and GABAA receptors Phytotherapy Research 21 2007 932 937 (Pubitemid 47582766)
26. W. Sieghart Structure and pharmacology of γ-aminobutyric acid A receptor subtypes Pharmacological Review 47 1995 181 234
27. W. Sieghart, J. Ramerstorfer, I. Sarto-Jackson, Z. Varagic, and M. Ernst A novel GABAA receptor pharmacology: drugs interacting with the α + β-interface British Journal of Pharmacology 2011 10.1111/j.1476-5381.2011. 01779.x Nov. 10 (Epub ahead of print)
28. l. Steru, R. Chermat, B. Thierry, and P. Simon The tail suspension test: a new method for screening antidepressants in mice Psychopharmacology 85 1985 367 370 (Pubitemid 15123115)
29. G. Trauner, S. Khom, I. Baburin, B. Benedek, S. Hering, and B. Kopp Modulation of GABAA receptors by valerian extracts is related to the content of valerenic acid Planta Medica 74 2008 19 24 (Pubitemid 351251378)
30. C.S. Yuan, S. Mehendale, Y. Xiao, H.H. Aung, J.T. Xie, and M.K. Ang-Lee The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity Anesthesia & Analgesia 98 2 2004 353 358 (Pubitemid 38129379)